References
- Rai SK, Burns LC, De Vera MA, et al. The economic burden of gout: a systematic review. Semin Arthritis Rheum 2015;45:75-80
- Singh JA. The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther 2014;16:R132
- Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6
- Mikuls TR, Saag KG. New insights into gout epidemiology. Curr Opin Rheumatol 2006;18:199-203
- Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
- Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136-41
- Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin 2006;22:1381-9
- Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp 2013;75:1-4
- Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46
- Khanna P, Khanna D, Storgard C, et al. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med 2016;128:34-40
- Juraschek SP, Kovell LC, Miller ER III, et al. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken) 2015;67:588-92
- Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004;10:308-14
- Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102-10
- Edwards NL, Sundy JS, Forsythe A, et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011;14:10-15
- Wu EQ, Forsythe A, Guerin A, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 2012;19:e157-e166
- Bolge SC, Doan JF, Kannan H, et al. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 2009;18:415-22
- DiBonaventura MD, Wagner JS, Yuan Y, et al. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010;13:709-18
- Finkelstein EA, Allaire BT, DiBonaventura MD, et al. Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. J Occup Environ Med 2011;53:1025-9
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65